Epstein-Barr virus latent membrane protein 2-derived peptide–HLA class I complex (EBV LMP2-HLA Class I complex)

Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2)-derived peptide–HLA class I complexes are critical immunological targets for treating EBV-associated malignancies, such as nasopharyngeal carcinoma and Hodgkin lymphoma (Young & Dawson, 2014, PMID: 24398350). LMP2 is a viral protein expressed during the latency II and III phases of the EBV life cycle, where it plays a role in maintaining viral persistence and promoting B-cell survival (Longnecker, 2000, PMID: 10933251). These complexes are formed when intracellular LMP2 is proteolytically processed into short peptides, which are then loaded onto Human Leukocyte Antigen (HLA) class I molecules and transported to the cell surface. This presentation allows CD8+ cytotoxic T lymphocytes (CTLs) to recognize and eliminate the tumor cells through T-cell receptor (TCR) binding (Hislop et al., 2007, PMID: 17440462). Because LMP2 is a non-self viral antigen, these complexes are highly attractive for precision immunotherapies, including TCR-engineered T cells (TCR-T) and therapeutic vaccines (Lin et al., 2018, PMID: 29439113). The "other" designation typically refers to complexes involving diverse HLA alleles beyond the common HLA-A*02:01, such as HLA-A*11:01 or HLA-A*24:02, which are prevalent in specific geographic populations where EBV-driven cancers are endemic. Targeting these complexes provides a pathway for treating patients with EBV-driven cancers that are otherwise resistant to conventional therapies.

Other names

LMP2-MHC class I complexEBV LMP2 peptide-HLA complexLatent membrane protein 2-HLA complexLMP2-derived epitope-HLA complexEBV LMP2-pMHC

Recognition of viral peptide-HLA complexes by T-cell receptors (TCRs) on CD8+ T cells to induce cytotoxic lysis of EBV-infected or transformed cells.